Your Health, We Care
Release date: 2026-03-12 16:57:15 Recommended: 52
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD).
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in adult patients.
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion in adult patients.
Waldenström's Macroglobulinemia (WM) in adult patients.
Chronic Graft-Versus-Host Disease (cGVHD) in adult and pediatric patients aged 1 year and older after failure of one or more systemic therapies.
Administration Method for Ibrutinib
Ibrutinib is administered orally, once daily.
Hemorrhage; Infections; Cardiac arrhythmias, heart failure, and sudden death; Hypertension; Cytopenias; Second primary malignancies; Tumor Lysis Syndrome (TLS); and Embryo-fetal toxicity.
Common adverse reactions in patients with B-cell malignancies (CLL/SLL and WM) include thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, and nausea.
Common adverse reactions in adult or pediatric patients with chronic Graft-Versus-Host Disease (cGVHD) include fatigue, anemia, bruising, diarrhea, thrombocytopenia, musculoskeletal pain, pyrexia, muscle spasms, stomatitis, hemorrhage, nausea, abdominal pain, pneumonia, and headache.
New Drug Application submitted to the U.S. FDA for ibrutinib for the treatment of two types of B-cell malignancies.
FDA approves ibrutinib for the treatment of mantle cell lymphoma.
FDA approves ibrutinib for the treatment of chronic lymphocytic leukemia.
FDA expands approved use of ibrutinib for the treatment of chronic lymphocytic leukemia.
FDA expands approved use of ibrutinib for the treatment of Waldenström's macroglobulinemia.
FDA approves ibrutinib for first-line treatment of chronic lymphocytic leukemia.
U.S. FDA expands ibrutinib label to include overall survival data in previously untreated chronic lymphocytic leukemia (CLL) and adds small lymphocytic lymphoma (SLL) patient indication.
U.S. FDA approves ibrutinib as the first drug specifically for the treatment of relapsed/refractory marginal zone lymphoma (MZL).
FDA approves ibrutinib for treatment of chronic graft-versus-host disease.
FDA approves ibrutinib in combination with rituximab for the treatment of patients with Waldenström's macroglobulinemia.
FDA approves ibrutinib plus obinutuzumab as the first non-chemotherapy combination for the treatment of patients with previously untreated chronic lymphocytic leukemia.
FDA approves ibrutinib in combination with rituximab for the treatment of chronic lymphocytic leukemia (CLL).
U.S. FDA approves ibrutinib as the first and only BTK inhibitor for the treatment of chronic graft-versus-host disease in pediatric patients aged 1 year and older.
Update on the accelerated approval of ibrutinib for mantle cell lymphoma and marginal zone lymphoma in the U.S.
Johnson & Johnson announces U.S. label expansion for ibrutinib to include oral suspension formulation for use in adult patients across approved indications.
